New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2012
08:36 EDTRGRXRegeneRx completes license agreement for development of RegeneRx products
RegeneRx announced that it has entered into a licensing agreement with Lee's Pharmaceutical Limited for the license to Lee's of RegeneRx's Thymosin Beta 4-based products, including the company's RGN-259, RGN-352 and RGN-137 product candidates, in China and Taiwan. Lee's previously paid RegeneRx $200,000 upon signing of a term sheet and will pay RegeneRx an additional $200,000 with the completion of this license agreement. The terms of the deal include aggregate potential milestone payments of up to $3.6M and royalties ranging from low double digit to high single digit royalties on commercial sales. RegeneRx also has the right to exclusively license any improvements made by Lee's to RegeneRx's products outside of the licensed territory.
News For RGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:26 EDTRGRXRegeneRx receives Israeli acceptance notice for use of TB4
RegeneRx announced that it has received a patent acceptance notice from the Israeli patent office with claims for administering Thymosin beta 4 to prevent or reduce tissue damage caused by an increase in blood flow, as is often the case when cardiac vessels are opened after a blockage causing a heart attack or in similar circumstances when treating stroke victims.
March 25, 2015
08:56 EDTRGRXRegeneRx receives initial payment for RGN-259 U.S. license
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use